Journal of Clinical Oncology

Vol. 43, Issue 16_suppl Issue 16_suppl 2025
6439
Articles

Articles in this Issue

Comparing the bleeding risk in hepatocellular carcinoma patients treated with atezolizumab/bevacizumab versus durvalumab plus tremelimumab.

Muhammad Mujtaba Bhinder, Ammad Naeem, Mohammad Khudayar et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e13882

e13882 Background: This study compares bleeding risk in hepatocellular carcinoma (HCC) patients receiving Atezolizumab/Bevacizumab (A+B) vs. Durvalumab/Tr...

Survival outcomes and patterns of care in ovarian carcinoma patients with brain metastases: A real-world analysis.

Fatma Nihan Akkoc Mustafayev, Khalis Mustafayev, Mohammad Arfat Ganiyani et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e14010

e14010 Background: Brain metastases (BM) from ovarian cancer (OC) are rare, with an estimated incidence of 0.5-2.4%. The rarity of these cases presents si...

Prognostic role of baseline levels and early changes of systemic inflammatory indexes for avelumab maintenance in metastatic urothelial carcinoma: The Meet-URO25a/SAILOR study.

Brigida Anna Maiorano, Marco Maruzzo, Pierangela Sepe et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e16572

e16572 Background: Avelumab maintenance after first-line platinum-based chemotherapy represents a cornerstone for the treatment of metastatic urothelial c...

Decoding the response and resistant features to the Claudin18.2-specific CAR-T cell CT041 in gastric cancer: A multi-omics exploratory biomarker analysis of the phase 1 clinical trial.

Haoxin Peng, Yang Chen, Dan Liu et al. Jun 01, 2025 pp. 4015-4015 10.1200/jco.2025.43.16_suppl.4015

4015 Background: CT041, a Claudin18.2-specific CAR-T cell therapy against gastric cancer (GC), has demonstrated encouraging efficacy and a manageable safe...

Immune related liver toxicity, management, and outcomes in ICI treated patients with advanced or metastatic cancers.

Zara Izadi, Youbei Lou, Ying Zhang et al. Jun 01, 2025 pp. 2599-2599 10.1200/jco.2025.43.16_suppl.2599

2599 Background: The impact of hepatic immune-related adverse events (HirAEs) and their management (mgmt) on clinical outcomes in patients receiving immun...

Spatial and bulk transcriptomic analysis of skin Kaposi sarcoma lesions: Differences by disease characteristics.

Quashawn Rakeem Chadwick, Ned Cauley, Nina Bubunenko et al. Jun 01, 2025 pp. 11530-11530 10.1200/jco.2025.43.16_suppl.11530

11530 Background: Kaposi sarcoma (KS) is an angioproliferative tumor caused by Kasposi sarcoma herpesvirus (KSHV) that typically manifests as skin lesions...

Postoperative radioiodine (RAI) versus no radiodine therapy for patients with low-risk differentiated thyroid cancer: A systematic review and meta-analysis.

Assaina Tatiana Jaquissone Tomo, Lívian Gonçalves, Gabriela Gazzoni et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e18157

e18157 Background: Postoperative radioiodine (RAI) treatment is commonly used for remnant ablation as a standard adjuvant therapy for patients with differ...

Impact of immigration status on survival amongst early-stage (1&2) HER2 positive and triple-negative breast cancer patients in Ontario, Canada.

Omolara Aminat Fatiregun, Rinku Sutradhar, Sho Podolsky et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e12512

e12512 Background: This study explored death from breast cancer and death from other causes amongst women with stages 1 and 2 her2 positive and triple-neg...

HexAgon-HN: Phase 2/3, randomized study of the hexavalent OX40 agonist INBRX-106 in combination with pembrolizumab vs pembrolizumab alone as first-line treatment for recurrent/metastatic head and neck cancer with a PD-L1 combined positive score of ≥20.

Jong Chul Park, Lisa F. Licitra, Aditya V. Shreenivas et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.tps6109

TPS6109 Background: Pembrolizumab (pembro) ± chemotherapy is a standard-of-care first-line treatment option for recurrent/metastatic (R/M) head and neck s...

Role of systematic biopsies in suspected prostate carcinoma patients and analysis of Gleason grade group concordance between the biopsy and histopathology report following radical prostatectomy.

Avijit Banerjee, Mohamad Ali, Gagan Gautam Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e17126

e17126 Background: In biopsy-naïve patients with suspicious lesions on MRI, magnetic resonance (MR) targeted biopsy of the lesion and systematic biopsy ar...

Prevalence of EGFR mutations in non-small cell lung cancer in Hawaii: A multi-center epidemiology study.

Toshiaki Takahashi, Evan Wu, Lani Park et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e22585

e22585 Background: Epidermal Growth Factor Receptor (EGFR) mutation analysis in non-small cell lung cancer (NSCLC) is crucial for navigating treatment dec...

Use of low-value cancer treatments in Medicare Advantage versus traditional Medicare.

Aaron Philip Mitchell, Caroline Carlin, Roger Feldman et al. Jun 01, 2025 pp. 11075-11075 10.1200/jco.2025.43.16_suppl.11075

11075 Background: Medicare Advantage (MA) has steadily grown during the past decade, covering over half of Medicare beneficiaries in 2024. Because MA plan...

Evaluation of AI-assisted PD-L1 CPS scoring in immunostained pan-organ tumor whole-slide images.

Céline Bossard, Claire Magois, Hélène Roussel et al. Jun 01, 2025 pp. 2631-2631 10.1200/jco.2025.43.16_suppl.2631

2631 Background: PD-L1 inhibitors have shown remarkable results in oncology, yet many patients fail to respond, underscoring the importance of reliable as...

Androgen suppression combined with elective nodal irradiation and dose escalated prostate treatment: A non-inferiority, phase III randomized controlled trial of stereotactic body radiation therapy versus brachytherapy boost in patients with unfavourable risk localized prostate cancer (ASCENDE-SBRT; CCTG PR24; NCT06235697).

Andrew Loblaw, Rachel Glicksman, Joelle Antoine Helou et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.tps5132

TPS5132 Background: External beam radiotherapy (EBRT), brachytherapy boost and androgen deprivation therapy (ADT) is the evidence-based standard of care f...

Geographical disparities and temporal trends in the prevalence of hospitalized esophageal carcinoma patients in the United States.

Jasneet Gill, Ayobami Gbenga Olafimihan, Michael Leahy et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e16161

e16161 Background: Esophageal cancer (EC) is a highly aggressive malignancy that remains a major cause of cancer-related morbidity and mortality worldwide...

Perioperative camrelizumab plus apatinib and gemcitabine-oxaliplatin in patients with borderline resectable biliary tract malignancies: A multicenter, single-arm, phase II trial.

Jianzhen Shan, Zhen Liu, Guoliang Qiao et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e16299

e16299 Background: Biliary tract malignancies are often diagnosed at advanced stages and carry a poor prognosis. While surgical resection remains the only...

Safety and efficacy of EIK1003, a selective PARP1 inhibitor, as monotherapy in participants with advanced solid tumors.

Guru P. Sonpavde, Drew W. Rasco, Jian Zhang et al. Jun 01, 2025 pp. 3122-3122 10.1200/jco.2025.43.16_suppl.3122

3122 Background: PARP inhibitors (PARPi) selectively kill tumor cells with genetic mutations in critical DNA repair genes (eg, BRCA1/2). While approved no...

Sintilimab combined with lenvatinib versus hepatic artery infusion chemotherapy (HAIC) for neoadjuvant treatment of resectable primary hepatocellular carcinoma with high risk of recurrence: A prospective, two-arm, randomized, phase II clinical study.

Feng Fang, Tianqiang Song, Qiang Wu et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e16301

e16301 Background: The high recurrence rate after resection is closely associated with poor prognosis for resectable hepatocellular carcinoma (HCC). There...

Socio-behavioral needs and prostate and breast cancer mortality rates in African Americans, Hispanics, and Non-Hispanic Whites: A national descriptive exploration within groups.

Valerie C Valerio, Talita Honorato-Rzeszewicz, Peter Smittenaar et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e13825

e13825 Background: While previous studies have identified higher mortality rates in African Americans diagnosed with prostate and breast cancer compared t...

Early onset cancer in Chile: 27-year mortality rate trends from a nationwide database with focus in gastrointestinal tumors.

Cristobal Tomas Sanhueza Condell, Iris Delgado Becerra, Jaime Anabalon et al. Jun 01, 2025 pp. 11169-11169 10.1200/jco.2025.43.16_suppl.11169

11169 Background: Cancer has historically been considered a disease of older adults, however, several reports have shown an alarming rise in the incidence...

Outpatient infusion sepsis protocol and outcomes for patients with cancer.

Ashley Miles, Helen Evers-Hunt, Adam F Binder et al. Jun 01, 2025 pp. 11135-11135 10.1200/jco.2025.43.16_suppl.11135

11135 Background: Sepsis, a life-threatening organ dysfunction caused by infection, is a common oncologic emergency in adult cancer patients. Early sepsis...

Cardiovascular complications of patients receiving CAR-T therapy.

Amina Jafar, Rabia Iqbal, Javeria Javeid et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e24019

e24019 Background: While highly effective for certain cancers, chimeric antigen receptor T-cell (CAR-T) therapy can lead to cardiovascular complications,...

Impact of graft-versus-host disease on mortality, length of stay, and hospitalization costs in bone marrow transplant patients: A retrospective analysis using the 2021 NIS database.

Srinishant Rajarajan, Kalaivani Babu, Charmi Bhanushali et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e18554

e18554 Background: Graft-versus-host disease (GVHD) is a significant complication of bone marrow transplantation (BMT), influencing patient outcomes, leng...

Who’s on the podium? Geographic and career diversity of ASCO Annual Meeting presenters.

Aysche Stern, Eduard Babayan, David Joseph Benjamin et al. Jun 01, 2025 pp. 9006-9006 10.1200/jco.2025.43.16_suppl.9006

9006 Background: The ASCO annual meeting is the world’s preeminent meeting of oncology professionals. Giving an oral presentation at the ASCO annual meeti...

The efficacy of METTL3 inhibition in pre-clinical models of MDS and AML.

Charles Kenworthy, Manyi Wei, Jennifer VanOudenhove et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e18584

e18584 Background: Splicing factor (SF) mutations commonly occur in myelodysplastic syndrome (MDS) and portend a poor prognosis. N6-methyladenosine (m...

All Issues

Journal Info

Publisher Lippincott Williams & Wilkins
ISSN 0732-183X
E-ISSN 1527-7755
Subject Health Sciences
Language English
View Full Journal Page